This year, the long-awaited FDA draft guidance for Platform Technology Designation Program was launched. This critical guidance allows drug developers to leverage Platform Technology data in approved drugs if similar “platforms” are used, accelerating the approval process and therapies to patients. In this webinar Catalent’s George Buchman will discuss Catalent’s approach to platform processes as well as securing an integrated supply chain. Siren’s Nathalie Clement will share Siren’s exciting work on combining two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single, powerful new treatment modality to fight cancer and how partnering with Catalent has allowed the acceleration of these offerings.